Talis Biomedical Balance Sheet Health
Financial Health criteria checks 6/6
Talis Biomedical has a total shareholder equity of $48.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $72.7M and $24.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$59.87m |
| Equity | US$48.63m |
| Total liabilities | US$24.07m |
| Total assets | US$72.70m |
Recent financial health updates
Recent updates
We're A Little Worried About Talis Biomedical's (NASDAQ:TLIS) Cash Burn Rate
Aug 16
Talis Biomedical reports Q2 results
Aug 02Talis Biomedical Aims For Manufacturing Turnaround
Mar 17Talis Biomedical (NASDAQ:TLIS) Will Have To Spend Its Cash Wisely
Feb 08Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?
Nov 04Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?
Jul 21News Flash: 4 Analysts Think Talis Biomedical Corporation (NASDAQ:TLIS) Earnings Are Under Threat
May 18Talis Biomedical Corporation (NASDAQ:TLIS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 14Financial Position Analysis
Short Term Liabilities: TLIS's short term assets ($63.6M) exceed its short term liabilities ($8.2M).
Long Term Liabilities: TLIS's short term assets ($63.6M) exceed its long term liabilities ($15.9M).
Debt to Equity History and Analysis
Debt Level: TLIS is debt free.
Reducing Debt: TLIS has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TLIS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: TLIS has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 0.8% each year.